A little over a year ago, Philippe Roussouly, his brother Jean-Charles, and Pierre, their father, a renowned orthopedic surgeon, were able to breathe a sigh of relief at the time of the IPO on Euronext Growth Paris , of SMAIO (Software, Machines and Adaptive Implants in Orthopaedics). An introduction accompanied by a fundraising of 9 million euros including 4.5 million euros subscribed by their American partner NuVasive, one of the world leaders in medical devices for spine surgery, 2 million euros from NextStage AM, 0.3 million euros from the historical shareholder Sylorus Scientific (the majority shareholder, the Roussouly family), the rest from the public.
An IPO that could never have seen the light of day without the stubbornness of the brothers…
